Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s

DeRenzo, Gottschalk (2020) Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s Adv Exp Med Biol (IF: 3.7) 1257 109-131

Abstract

T-cell immunotherapy may offer an approach to improve outcomes for patients with osteosarcoma who fail current therapies. In addition, it has the potential to reduce treatment-related complications for all patients. Generating tumor-specific T cells with conventional antigen-presenting cells ex vivo is time-consuming and often results in T-cell products with a low frequency of tumor-specific T cells. Furthermore, the generated T cells remain sensitive to the immunosuppressive tumor microenvironment. Genetic modification of T cells is one strategy to overcome these limitations. For example, T cells can be genetically modified to render them antigen specific, resistant to inhibitory factors, or increase their ability to home to tumor sites. Most genetic modification strategies have only been evaluated in preclinical models; however, early clinical phase trials are in progress. In this chapter, we will review the current status of gene-modified T-cell therapy with special focus on osteosarcoma, highlighting potential antigenic targets, preclinical and clinical studies, and strategies to improve current T-cell therapy approaches.

Links

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385999
http://www.ncbi.nlm.nih.gov/pubmed/32483735
http://dx.doi.org/10.1007/978-3-030-43032-0_10

Similar articles

Tools

Export to RIS